JPH11139970A - Oral solution - Google Patents

Oral solution

Info

Publication number
JPH11139970A
JPH11139970A JP30404297A JP30404297A JPH11139970A JP H11139970 A JPH11139970 A JP H11139970A JP 30404297 A JP30404297 A JP 30404297A JP 30404297 A JP30404297 A JP 30404297A JP H11139970 A JPH11139970 A JP H11139970A
Authority
JP
Japan
Prior art keywords
diclofenac
solution
appropriate amount
added
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP30404297A
Other languages
Japanese (ja)
Inventor
Tomohiko Osugi
智彦 大杉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOUJIN IYAKU KAKO KK
Original Assignee
DOUJIN IYAKU KAKO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOUJIN IYAKU KAKO KK filed Critical DOUJIN IYAKU KAKO KK
Priority to JP30404297A priority Critical patent/JPH11139970A/en
Publication of JPH11139970A publication Critical patent/JPH11139970A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain an oral solution reduced in or freed of a bitter taste and an irritant feeling of diclofenac or its salt to a throat. SOLUTION: This oral solution is obtained by carrying out a heating treatment of diclofenac or its salt in the presence of a flavoring agent. The flavoring agent is one or more selected from glycine, glycyrrhetinic acid and salts thereof. The heating treatment is carried out at 50-80 deg.C temperature.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、服用時の苦味や咽
喉への刺激感が軽減又は除去されたジクロフェナク経口
液剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an oral solution of diclofenac in which bitterness and irritation to the throat during administration are reduced or eliminated.

【0002】[0002]

【従来の技術】ジクロフェナクは、優れた鎮痛、抗炎
症、解熱作用を有する薬物で、多くの錠剤、カプセル剤
が上市されている。しかし、錠剤、カプセル剤は、高齢
者、重篤な患者には、服用しにくいという欠点があり、
服用しやすい経口液剤とすることが望まれていた。
2. Description of the Related Art Diclofenac is a drug having excellent analgesic, anti-inflammatory and antipyretic effects, and many tablets and capsules are on the market. However, tablets and capsules have the drawback of being difficult to take for elderly and serious patients,
There has been a demand for an oral solution that is easy to take.

【0003】しかしながら、ジクロフェナク又はその塩
は、服用時の苦味と咽喉への強い刺激感を有するため、
服用感の良い経口液剤を得ることは困難であった。
However, diclofenac or a salt thereof has a bitter taste when taken and a strong irritating feeling to the throat,
It was difficult to obtain a good oral liquid preparation.

【0004】これに対し、ジクロフェナクの苦味、刺激
感を低減する方法が開示されているが(特開平2−17
8224号公報)、この方法でも満足できる服用感は得
られていない。
On the other hand, a method has been disclosed for reducing the bitterness and irritation of diclofenac (Japanese Patent Laid-Open No. 2-17).
No. 8224), even with this method, a satisfactory feeling of ingestion has not been obtained.

【0005】[0005]

【発明が解決しようとする課題】従って本発明の目的
は、ジクロフェナク又はその塩の苦味及び咽喉への刺激
感が軽減又は除去された経口液剤を提供することにあ
る。
SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide an oral liquid preparation in which the bitterness of diclofenac or a salt thereof and the irritating feeling to the throat are reduced or eliminated.

【0006】[0006]

【課題を解決するための手段】斯かる実状に鑑み本発明
者は鋭意研究を行なったところ、ジクロフェナク又はそ
の塩を矯味剤の存在下加温処理すれば、服用時の苦味、
咽喉への刺激感が軽減又は除去された経口液剤が得られ
ることを見出し本発明を完成した。
Means for Solving the Problems In view of this situation, the present inventors have conducted intensive studies and found that diclofenac or a salt thereof can be heated to a bitter taste in the presence of a flavoring agent,
The present inventors have found that an oral liquid preparation with reduced or eliminated irritation to the throat can be obtained, and completed the present invention.

【0007】すなわち、本発明は、ジクロフェナク又は
その塩を矯味剤の存在下加温処理して得られる経口液剤
を提供するものである。
That is, the present invention provides an oral liquid preparation obtained by heating diclofenac or a salt thereof in the presence of a flavoring agent.

【0008】[0008]

【発明の実施の形態】本発明に用いるジクロフェナクの
塩としては、ナトリウム、カリウム等のアルカリ金属
塩;カルシウム、マグネシウム等のアルカリ土類金属
塩;アンモニウム塩;ジメチルアミン、ジエチルアミ
ン、トリメチルアミン、トリエチルアミン等のアルキル
金属塩;モノエタノールアミン、ジエタノールアミン、
ジイソプロパノールアミン、トリエタノールアミン、ト
リイソプロパノールアミン等の第1級、第2級又は第3
級のアルカノールアミンの塩が挙げられる。このうち、
ナトリウム塩が特に好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION The salt of diclofenac used in the present invention includes: alkali metal salts such as sodium and potassium; alkaline earth metal salts such as calcium and magnesium; ammonium salts; Alkyl metal salts; monoethanolamine, diethanolamine,
Primary, secondary or tertiary such as diisopropanolamine, triethanolamine, triisopropanolamine, etc.
And alkanolamine salts. this house,
Sodium salts are particularly preferred.

【0009】ジクロフェナク又はその塩は、経口液剤1
mLあたり0.01〜1000mg使用することが好まし
い。
[0009] Diclofenac or a salt thereof is used as an oral solution 1
It is preferable to use 0.01 to 1000 mg per mL.

【0010】本発明で使用する矯味剤としては、グリシ
ン、グリチルリチン酸又はその塩等が挙げられる。この
うちグリチルリチン酸は、そのものでも、これを含有す
る生薬であってもよい。またグリチルリチン酸の塩とし
ては、ナトリウム、カリウム等のアルカリ金属塩、アン
モニウム塩等が挙げられる。グリシン、グリチルリチン
酸又はその塩の添加量は、経口液剤1mLあたり0.01
〜200mg程度にすることが好ましく、特に1〜50mg
程度が好ましい。
[0010] The flavoring agent used in the present invention includes glycine, glycyrrhizic acid or a salt thereof. Of these, glycyrrhizic acid may be itself or a crude drug containing it. Examples of the salt of glycyrrhizic acid include alkali metal salts such as sodium and potassium, and ammonium salts. The addition amount of glycine, glycyrrhizic acid or a salt thereof is 0.01 per 1 mL of the oral solution.
~ 200mg is preferred, especially 1 ~ 50mg
The degree is preferred.

【0011】本発明の経口液剤は、上記成分以外に、通
常経口液剤に用いられる増粘剤、懸濁化剤、緩衝剤、安
定化剤、防腐剤、界面活性剤、着香料等を必要により用
いてもよい。
The oral solution of the present invention may contain, in addition to the above-mentioned components, a thickener, a suspending agent, a buffer, a stabilizer, a preservative, a surfactant, a flavoring agent, etc. which are usually used in an oral solution. May be used.

【0012】また、本発明の経口液剤のpHは、1.5〜
5.5の範囲内とすることが好ましく、特に3.0〜
5.0の範囲内とすることが好ましい。
The oral solution of the present invention has a pH of 1.5 to 1.5.
It is preferable to set it within the range of 5.5, and especially 3.0 to 3.0
It is preferable to be within the range of 5.0.

【0013】本発明の経口液剤は、例えば、水に防腐
剤、精製白糖等を溶解し、この溶液に矯味剤、必要によ
り増粘剤、懸濁剤等を加え均一に分散又は溶解し、次い
でジクロフェナク又はその塩を加え、必要により界面活
性剤を加え、これを均一に分散又は溶解し、必要により
水酸化ナトリウム等でpHを上記範囲に調整し、加温処理
をすることにより製造することができる。
The oral liquid preparation of the present invention is prepared, for example, by dissolving a preservative, purified sucrose and the like in water, adding a flavoring agent and, if necessary, a thickener and a suspending agent to the solution, and uniformly dispersing or dissolving. Diclofenac or a salt thereof is added, if necessary, a surfactant is added, and this is uniformly dispersed or dissolved.If necessary, the pH is adjusted to the above range with sodium hydroxide or the like, and the mixture can be produced by heating. it can.

【0014】加温処理は、40℃以上とすることが好ま
しく、特に50〜80℃の範囲で行なうことが好まし
い。また加温処理の時間は、10〜60分程度が好まし
く、特に20〜30分程度が好ましい。
The heating treatment is preferably carried out at a temperature of 40 ° C. or higher, particularly preferably in the range of 50 to 80 ° C. The heating time is preferably about 10 to 60 minutes, particularly preferably about 20 to 30 minutes.

【0015】[0015]

【発明の効果】本発明の経口液剤は、ジクロフェナクの
苦味及び咽喉への刺激感が軽減又は除去されており、服
用感が良好である。
EFFECT OF THE INVENTION The oral liquid preparation of the present invention has a reduced or eliminated bitter taste of diclofenac and a feeling of irritation to the throat, and has a good feeling of taking.

【0016】[0016]

【実施例】以下、実施例を挙げて本発明を更に詳細に説
明するが、本発明は、これら実施例に限定されるもので
はない。
EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.

【0017】比較例1 防腐剤、精製白糖を溶解し、その溶液に増粘剤、懸濁化
剤を加え均一に分散した。これに、ジクロフェナクNa
と界面活性剤を加え均一に分散した。その後、水酸化ナ
トリウムを添加しpHを6.0に調整し、香料を添加し
た。その溶液を更に均一に分散し、精製水にて全量を1
00mLとし、経口液剤とした。
Comparative Example 1 A preservative and purified sucrose were dissolved, and a thickener and a suspending agent were added to the solution to uniformly disperse it. Add diclofenac Na
And a surfactant were added and dispersed uniformly. Thereafter, sodium hydroxide was added to adjust the pH to 6.0, and a fragrance was added. The solution was dispersed more uniformly, and the total amount was
The solution was made up to 00 mL to give an oral solution.

【0018】[0018]

【表1】 (100mL中処方) ジクロフェナクNa 750mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purified sucrose 40 g Hydrochloric acid Appropriate amount Water Sodium oxide appropriate amount Preservatives appropriate amount Fragrance trace amount Total amount in purified water 100mL

【0019】比較例2 ソルビン酸、ソルビトール液を溶解し、その溶液にヒド
ロキシエチルセルロース、結晶セルロース・カルメロー
スナトリウムを加え均一に分散した。その後アスコルビ
ン酸、クエン酸、サッカリンナトリウムを加え均一に分
散した。その溶液にジクロフェナクを添加し更に均一に
分散し、液量を補正し、経口液剤とした。
Comparative Example 2 Sorbic acid and sorbitol solution were dissolved, and hydroxyethyl cellulose and crystalline cellulose / carmellose sodium were added to the solution and uniformly dispersed. Thereafter, ascorbic acid, citric acid and saccharin sodium were added and dispersed uniformly. Diclofenac was added to the solution, and the mixture was further uniformly dispersed, and the amount of the solution was corrected to obtain an oral liquid preparation.

【0020】[0020]

【表2】 (100mL中処方) ジクロフェナク 750mg ヒドロキシエチルセルロース 500mg 結晶セルロース・カルメロースナトリウム 1.2g ソルビトール液 25g ソルビン酸 50mg アスコルビン酸 100mg サッカリンナトリウム 60mg クエン酸 200mg 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac 750 mg Hydroxyethyl cellulose 500 mg Crystalline cellulose / carmellose sodium 1.2 g Sorbitol solution 25 g Sorbic acid 50 mg Ascorbic acid 100 mg Saccharin sodium 60 mg Citric acid 200 mg Purified water 100 mL

【0021】実施例1 防腐剤、精製白糖を溶解し、その溶液に増粘剤、懸濁化
剤、矯味剤(グリシン)を加え均一に分散した。これ
に、ジクロフェナクNaと界面活性剤を加え均一に分散
した。その後、水酸化ナトリウムを添加しpHを4.5に
調整し、香料を添加した。その溶液を更に均一に分散
し、精製水にて全量を100mLとした。この後、70℃
にて20分間加温処理し、経口液剤とした。
Example 1 A preservative and purified sucrose were dissolved, and a thickener, a suspending agent, and a flavoring agent (glycine) were added to the solution and uniformly dispersed. To this, diclofenac Na and a surfactant were added and uniformly dispersed. Thereafter, sodium hydroxide was added to adjust the pH to 4.5, and a fragrance was added. The solution was further uniformly dispersed, and the total amount was adjusted to 100 mL with purified water. After this, 70 ° C
For 20 minutes to give an oral solution.

【0022】[0022]

【表3】 (100mL中処方) ジクロフェナクNa 750mg グリシン 50mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycine 50 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purified sucrose 40 g Hydrochloric acid Appropriate amount Sodium hydroxide Appropriate amount Preservatives Appropriate amount Fragrance trace amount Total amount in purified water 100mL

【0023】実施例2 実施例1と同様の方法にて下記処方成分を含有するシロ
ップ剤を得た。
Example 2 A syrup containing the following ingredients was obtained in the same manner as in Example 1.

【0024】[0024]

【表4】 (100mL中処方) ジクロフェナクNa 750mg グリシン 100mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycine 100 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purified sucrose 40 g Hydrochloric acid Appropriate amount Sodium hydroxide Appropriate amount Preservatives Appropriate amount Fragrance trace amount Total amount in purified water 100mL

【0025】実施例3 実施例1と同様の方法にて下記処方成分を含有するシロ
ップ剤を得た。
Example 3 A syrup containing the following ingredients was obtained in the same manner as in Example 1.

【0026】[0026]

【表5】 (100mL中処方) ジクロフェナクNa 750mg グリチルリチン酸 50mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycyrrhizic acid 50 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purified sucrose 40 g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount Total amount in purified water 100mL

【0027】実施例4 実施例1と同様の方法にて下記処方成分を含有するシロ
ップ剤を得た。
Example 4 A syrup containing the following ingredients was obtained in the same manner as in Example 1.

【0028】[0028]

【表6】 (100mL中処方) ジクロフェナクNa 750mg グリチルリチン酸 100mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycyrrhizic acid 100 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purified sucrose 40 g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount Total amount in purified water 100mL

【0029】実施例5 実施例1と同様の方法にて下記処方成分を含有するシロ
ップ剤を得た。
Example 5 A syrup containing the following ingredients was obtained in the same manner as in Example 1.

【0030】[0030]

【表7】 (100mL中処方) ジクロフェナクNa 750mg グリシン 50mg グリチルリチン酸 50mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mLTable 7 (Prescription in 100 mL) Diclofenac Na 750 mg Glycine 50 mg Glycyrrhizic acid 50 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purification Sucrose 40g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount

【0031】実施例6 実施例1と同様の方法にて下記処方成分を含有するシロ
ップ剤を得た。
Example 6 A syrup containing the following ingredients was obtained in the same manner as in Example 1.

【0032】[0032]

【表8】 (100mL中処方) ジクロフェナクNa 750mg グリシン 100mg グリチルリチン酸 100mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycine 100 mg Glycyrrhizic acid 100 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purification Sucrose 40g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount

【0033】試験例1 上記に示した検体について、10人の健常な成人ボラン
ティアにより官能試験を行なった。官能評価は、苦味及
び咽喉への刺激感について下記の基準に従い行なった。
結果を表9、10に示す。
Test Example 1 A sensory test was conducted on the above-mentioned specimens by 10 healthy adult volunteers. The sensory evaluation was performed according to the following criteria for bitterness and irritation to the throat.
The results are shown in Tables 9 and 10.

【0034】苦味の官能評価 1:苦い 2:やや苦い 3:殆ど苦くない 4:全く苦くないSensory evaluation of bitterness 1: bitter 2: slightly bitter 3: hardly bitter 4: not bitter at all

【0035】刺激感の官能評価 1:感じる 2:やや感じる 3:殆ど感じない 4:全く感じないSensory evaluation of feeling of irritation 1: Feel 2: Feel slightly 3: Feel almost no 4: Feel no

【0036】[0036]

【表9】 [Table 9]

【0037】[0037]

【表10】 [Table 10]

【0038】表9、表10のように、グリシン又はグリ
チルリチン酸の添加により、ジクロフェナク経口液剤の
服用感が向上した。
As shown in Tables 9 and 10, the addition of glycine or glycyrrhizic acid improved the feeling of taking the oral solution of diclofenac.

【0039】温度条件の検討 本経口液剤は、矯味剤の添加且つ加温処理することによ
り、服用感が向上するものである。そこで、以下の実施
例で温度条件について検討を行なった。
Examination of Temperature Conditions The present oral liquid preparation is intended to improve the feeling of ingestion by adding a flavoring agent and heating. Then, the temperature conditions were studied in the following examples.

【0040】実施例7 防腐剤、精製白糖を溶解し、その溶液に増粘剤、懸濁化
剤、グリシン、グリチルリチン酸を加え均一に分散し
た。これに、ジクロフェナクNaと界面活性剤を加え均
一に分散した。その後、水酸化ナトリウムを添加しpHを
4.5に調整し、香料を添加した。その溶液を更に均一
に分散し、精製水にて全量を100mLとし、経口液剤と
した。
Example 7 A preservative and purified sucrose were dissolved, and a thickener, a suspending agent, glycine, and glycyrrhizic acid were added to the solution and uniformly dispersed. To this, diclofenac Na and a surfactant were added and uniformly dispersed. Thereafter, sodium hydroxide was added to adjust the pH to 4.5, and a fragrance was added. The solution was further uniformly dispersed, and the total amount was made up to 100 mL with purified water to prepare an oral liquid preparation.

【0041】[0041]

【表11】 (100mL中処方) ジクロフェナクNa 750mg グリシン 100mg グリチルリチン酸 100mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycine 100 mg Glycyrrhizic acid 100 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purification Sucrose 40g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount

【0042】実施例8 防腐剤、精製白糖を溶解し、その溶液に増粘剤、懸濁化
剤、グリシン、グリチルリチン酸を加え均一に分散し
た。これに、ジクロフェナクNaと界面活性剤を加え均
一に分散した。その後、水酸化ナトリウムを添加しpHを
4.5に調整し、香料を添加した。その溶液を更に均一
に分散し、精製水にて全量を100mLとした。この後、
40℃にて20分間加温処理し、経口液剤とした。
Example 8 A preservative and purified sucrose were dissolved, and a thickener, a suspending agent, glycine and glycyrrhizic acid were added to the solution and uniformly dispersed. To this, diclofenac Na and a surfactant were added and uniformly dispersed. Thereafter, sodium hydroxide was added to adjust the pH to 4.5, and a fragrance was added. The solution was further uniformly dispersed, and the total amount was adjusted to 100 mL with purified water. After this,
The solution was heated at 40 ° C. for 20 minutes to give an oral liquid preparation.

【0043】[0043]

【表12】 (100mL中処方) ジクロフェナクNa 750mg グリシン 100mg グリチルリチン酸 100mg 界面活性剤(ショ糖脂肪酸エステル) 25mg 増粘剤(カルボキシビニルポリマー) 400mg 懸濁化剤(結晶セルロース・カルメロースナトリウム) 1g 精製白糖 40g 塩酸 適量 水酸化ナトリウム 適量 防腐剤 適量 香料 微量 精製水にて全量 100mL(Prescription in 100 mL) Diclofenac Na 750 mg Glycine 100 mg Glycyrrhizic acid 100 mg Surfactant (sucrose fatty acid ester) 25 mg Thickener (carboxyvinyl polymer) 400 mg Suspending agent (crystalline cellulose / carmellose sodium) 1 g Purification Sucrose 40g Hydrochloric acid appropriate amount Sodium hydroxide appropriate amount Preservatives appropriate amount Fragrance trace amount

【0044】実施例9 補正後の加温処理温度を50℃にする以外、実施例8と
同様の方法にて行ない、同様な処方成分を含有するシロ
ップ剤を得た。
Example 9 A syrup containing the same prescription components was obtained in the same manner as in Example 8, except that the corrected heating temperature was changed to 50 ° C.

【0045】実施例10 補正後の加温処理温度を60℃にする以外、実施例8と
同様の方法にて行ない、同様な処方成分を含有するシロ
ップ剤を得た。
Example 10 A syrup containing the same prescription components was obtained in the same manner as in Example 8, except that the corrected heating temperature was set to 60 ° C.

【0046】実施例11 補正後の加温処理温度を70℃にする以外、実施例8と
同様の方法にて行ない、同様な処方成分を含有するシロ
ップ剤を得た。
Example 11 A syrup containing the same ingredients was obtained in the same manner as in Example 8, except that the corrected heating temperature was 70 ° C.

【0047】実施例12 補正後の加温処理温度を80℃にする以外、実施例8と
同様の方法にて行ない、同様な処方成分を含有するシロ
ップ剤を得た。
Example 12 A syrup containing the same formulation was obtained in the same manner as in Example 8, except that the corrected heating temperature was set to 80 ° C.

【0048】試験例2 上記に示した検体について、試験例1と同じ試験方法に
て比較した。結果を表13、表14に示す。
Test Example 2 The samples shown above were compared by the same test method as in Test Example 1. The results are shown in Tables 13 and 14.

【0049】[0049]

【表13】 [Table 13]

【0050】[0050]

【表14】 [Table 14]

【0051】表13、表14のように、加温処理温度を
40℃以上、特に50℃以上にすることにより、ジクロ
フェナク経口液剤の服用感が向上した。
As shown in Tables 13 and 14, by setting the heating treatment temperature to 40 ° C. or higher, particularly to 50 ° C. or higher, the feeling of taking the oral liquid solution of diclofenac was improved.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ジクロフェナク又はその塩を矯味剤の存
在下加温処理して得られる経口液剤。
An oral liquid preparation obtained by heating diclofenac or a salt thereof in the presence of a flavoring agent.
【請求項2】 矯味剤がグリシン、グリチルリチン酸及
びその塩から選ばれる1種又は2種以上である請求項1
記載の経口液剤。
2. The flavoring agent is one or more selected from glycine, glycyrrhizic acid and salts thereof.
The oral solution according to the above.
【請求項3】 加温処理が50〜80℃の温度で行なわ
れる請求項1記載の経口液剤。
3. The oral liquid preparation according to claim 1, wherein the heating treatment is performed at a temperature of 50 to 80 ° C.
JP30404297A 1997-11-06 1997-11-06 Oral solution Pending JPH11139970A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP30404297A JPH11139970A (en) 1997-11-06 1997-11-06 Oral solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30404297A JPH11139970A (en) 1997-11-06 1997-11-06 Oral solution

Publications (1)

Publication Number Publication Date
JPH11139970A true JPH11139970A (en) 1999-05-25

Family

ID=17928359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP30404297A Pending JPH11139970A (en) 1997-11-06 1997-11-06 Oral solution

Country Status (1)

Country Link
JP (1) JPH11139970A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004067516A (en) * 2002-08-01 2004-03-04 Rohto Pharmaceut Co Ltd Solution for oral use
JP2007514701A (en) * 2003-12-19 2007-06-07 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ Orally administered preparations with non-steroidal anti-inflammatory drugs and good taste
JP2008174501A (en) * 2007-01-19 2008-07-31 Ss Pharmaceut Co Ltd Oral composition
JP2009018993A (en) * 2007-07-10 2009-01-29 Towa Yakuhin Kk Uncomfortable taste-masked quinolone-based antibiotic oral administration liquid medicine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004067516A (en) * 2002-08-01 2004-03-04 Rohto Pharmaceut Co Ltd Solution for oral use
JP2007514701A (en) * 2003-12-19 2007-06-07 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ Orally administered preparations with non-steroidal anti-inflammatory drugs and good taste
JP2008174501A (en) * 2007-01-19 2008-07-31 Ss Pharmaceut Co Ltd Oral composition
JP2009018993A (en) * 2007-07-10 2009-01-29 Towa Yakuhin Kk Uncomfortable taste-masked quinolone-based antibiotic oral administration liquid medicine

Similar Documents

Publication Publication Date Title
JP4445590B2 (en) Oral liquid composition containing paroxetine-resin
KR950009090B1 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
PT742714E (en) LIQUID PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THYROID HORMONES
JP4051717B2 (en) Biotin-containing oral solution
JPH0782150A (en) Liquid-dosage type medicine containing ursodeoxycholic acid
JPH0813737B2 (en) Syrup
JP2001031562A (en) Liquid preparation for internal use
JP4580921B2 (en) Pharmaceutical composition comprising 5-methyl-2- (2'-chloro-6'-fluoroanilino) phenylacetic acid
JPH11139970A (en) Oral solution
JP3805646B2 (en) Pharmaceutical solution
CA3157999A1 (en) Injectable compositions of ursodeoxycholic acid
JPH09502709A (en) Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt
JPH08295637A (en) Local administrative agent for oral cavity
JP4959864B2 (en) Glutamate-containing solution
KR101297354B1 (en) Stable and taste masking syrup composition of transparent solution comprising Dexibuprofen
US3109773A (en) Bronchodilator expectorant composition containing theophylline and a guaiacol
JPH1036252A (en) Oral liquid medicine combined with belladonna (total) alkaloid
JP3534793B2 (en) Glycyrrhizinate rectal formulation
USRE29359E (en) Bronchodilator expectorant composition containing theophylline and a guaiacol
JPS63313725A (en) Syrup agent
JPH05124963A (en) Theophylline-containing liquid agent
KR0129787B1 (en) Solubilization method of cold drugs centering ibuprofen
JPH02221213A (en) Skin cosmetic
JP2003342186A (en) Oral liquid formulation composition for rhinitis
JP2516481B2 (en) Anti-inflammatory analgesic gel formulation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040525

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040525

A131 Notification of reasons for refusal

Effective date: 20080520

Free format text: JAPANESE INTERMEDIATE CODE: A131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106